<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="other" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">The Clinician</journal-id><journal-title-group><journal-title xml:lang="en">The Clinician</journal-title><trans-title-group xml:lang="ru"><trans-title>Клиницист</trans-title></trans-title-group></journal-title-group><issn publication-format="print">1818-8338</issn><issn publication-format="electronic">2412-8775</issn><publisher><publisher-name xml:lang="en">Publishing House ABV Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">308</article-id><article-id pub-id-type="doi">10.17650/1818-8338-2017-11-2-24-32</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>REVIEW</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>ОБЗОР</subject></subj-group><subj-group subj-group-type="article-type"><subject></subject></subj-group></article-categories><title-group><article-title xml:lang="en">THROMBOTIC AND THROMBOEMBOLIC COMPLICATIONS IN SYSTEMIC VASCULITIS</article-title><trans-title-group xml:lang="ru"><trans-title>ТРОМБОТИЧЕСКИЕ И ТРОМБОЭМБОЛИЧЕСКИЕ ОСЛОЖНЕНИЯ ПРИ СИСТЕМНЫХ ВАСКУЛИТАХ</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Arseniev</surname><given-names>E. V.</given-names></name><name xml:lang="ru"><surname>Арсеньев</surname><given-names>Е. В.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>34A Kashirskoe Shosse, Moscow 115522.</p></bio><bio xml:lang="ru"><p>115522 Москва, Каширское шоссе, 34А.</p></bio><email>evgeniyarsenjev@yandex.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Topolyanskaya</surname><given-names>S. V.</given-names></name><name xml:lang="ru"><surname>Тополянская</surname><given-names>С. В.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>8 Trubetskaya St., Moscow 119991.</p></bio><bio xml:lang="ru"><p>119991 Москва, ул. Трубецкая, 8.</p></bio><xref ref-type="aff" rid="aff2"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">V.A. Nasonova Research Institute of Rheumatology.</institution></aff><aff><institution xml:lang="ru">ФГБНУ «Научно-исследовательский институт ревматологи им. В.А. Насоновой».</institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en">I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia.</institution></aff><aff><institution xml:lang="ru">ФГАОУ ВО «Первый Московский государственный университет им. И.М. Сеченова» Минздрава России.</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2017-04-15" publication-format="electronic"><day>15</day><month>04</month><year>2017</year></pub-date><volume>11</volume><issue>2</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>24</fpage><lpage>32</lpage><history><date date-type="received" iso-8601-date="2017-12-18"><day>18</day><month>12</month><year>2017</year></date><date date-type="accepted" iso-8601-date="2017-12-18"><day>18</day><month>12</month><year>2017</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2017, Arseniev E.V., Topolyanskaya S.V.</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2017, Арсеньев Е.В., Тополянская С.В.</copyright-statement><copyright-year>2017</copyright-year><copyright-holder xml:lang="en">Arseniev E.V., Topolyanskaya S.V.</copyright-holder><copyright-holder xml:lang="ru">Арсеньев Е.В., Тополянская С.В.</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://klinitsist.abvpress.ru/Klin/article/view/308">https://klinitsist.abvpress.ru/Klin/article/view/308</self-uri><abstract xml:lang="en"><p>Nowadays, there is no doubt about the relationship between immune inflammation and the development of thrombosis due to the similarity of many pathogenetic machanisms underlying both pathological processes. Systemic vasculitis, along with other immuno- mediated inflammatory diseases, represent one of the most clear examples of such interaction. Thrombotic complications remain one of the most serious and life-threatening conditions that occur in patients with autoimmune diseases, in particular systemic vasculitis. This serves as powerful stimulus for studing the problem of hypercoagulation, which often accompanies the course of systemic vasculitis. Of interest are thrombosis that occure both in the injury of large vessel and in the involvement of medium and small vessels in the pathological process. According to the literature, thrombotic and thromboembolic complications are most common in ANCA-associated vasculitis and Behçet’s disease. This review discusses current studies regarding features of clinical picture and mechanisms of thrombosis development in systemic vasculitis. Because of these studies it became clear that for some vasculitis a high frequency of both arterial and venous thrombosis is characteristic. At the same time, other vasculitis are accompanied by high risk of only venous thrombosis. Finally, thrombosis and thromboembolism are quite rare complications for some vasculitis. Among the presented mechanisms of thrombosis involvement, disruptions of the hemostasis are widely considered. For examples, the presents the results of researches, which is actively discussed the role of neutrophil extracellular traps and antiendothelial cell antibodies in the development on thrombotic complictions. Special attention is paid to the possible role of some disorders of hemostasis, such as polymorphism V coagulation factor G1691FA and prothrombin G20210A. To search for literature sources, the following queries were used: “vasculitis”, “thrombosis”, “neutrophil extracellular traps”, “ANCA-associated vasculitis”, “venous thrombosis”, “arterial thrombosis”, “Behçet’s disease”, “Takayasu arteritis”, “granulomatosis with polyangiitis”, “eosinophilic granulomatosis with polyangiitis”, “Mmicroscopic polyangiitis”, “Henoch–Schönlein purpura”, “Kawasaki disease”, “polyarteritis nodosa”, “giant cell arteritis”, “Buerger’s disease”. In addition, use similar requests in English. The search was carried out in PubMed.</p></abstract><trans-abstract xml:lang="ru"><p>На сегодняшний день не вызывает сомнений наличие взаимосвязи между иммунным воспалением и развитием тромбозов в силу схожести множества патогенетических механизмов, лежащих в основе обоих патологических процессов. Системные васкулиты, наряду с другими иммуновоспалительными заболеваниями, представляют собой один из ярких примеров подобной взаимосвязи. Тромботические осложнения остаются одними из самых серьезных и жизнеугрожающих состояний, возникающих у больных с системными васкулитами. Это служит мощным стимулом для изучения проблемы гиперкоагуляции, которая нередко сопровождает течение системных васкулитов. Интерес представляют собой тромбозы, возникающие как при поражении крупных сосудов, так и при вовлечении в патологический процесс сосудов среднего и малого калибра. По данным литературы, тромботические и тромбоэмболические осложнения наиболее часто встречаются при васкулитах, ассоциированных с антинейтрофильными цитоплазматическими антителами (АНЦА), и болезни Бехчета. В обзоре обсуждаются современные исследования, касающиеся особенностей клинической картины и механизмов развития тромбозов при системных васкулитах. Благодаря этим работам стало понятно, что для некоторых форм васкулитов характерна высокая частота как артериальных, так и венозных тромбозов; в то же время другие васкулиты сопровождаются высоким риском лишь венозных тромбозов. Наконец, для некоторых васкулитов тромбозы и тромбоэмболии являются достаточно редкими осложнениями. Среди представленных механизмов развития тромбозов широко рассматриваются нарушения работы гемостаза. Так, например, в статье представлены результаты исследований, в которых активно обсуждается роль внеклеточных нейтрофильных ловушек и антиэндотелиальных антител в развитии тромботических осложнений. Особое внимание уделяется возможной роли некоторых нарушений гемостаза, таких как полиморфизм V фактора коагуляции G1691FA и протромбина G20 210A. Для поиска источников литературы были использованы следующие поисковые запросы: «васкулиты», «тромбозы», «нейтрофильные внеклеточные ловушки», «АНЦА-ассоциированные васкулиты», «венозные тромбозы», «артериальные тромбозы», «болезнь Бехчета», «артериит Такаясу», «гранулематоз с полиангиитом», «эозинофильный гранулематоз с полиангиитом», «микроскопический полиангиит», «пурпура Шенлейна–Геноха», «болезнь Кавасаки», «узелковый периартериит», «гигантоклеточный артериит», «болезнь Бюргера». Кроме того, использовалиись аналогичные запросы на английском языке. Процедура поиска осуществлялась в базах PubMed.</p></trans-abstract><kwd-group xml:lang="en"><kwd>vasculitis</kwd><kwd>thrombosis</kwd><kwd>neutrophil extracellular traps</kwd><kwd>ANCA-associated vasculitis</kwd><kwd>venous thrombosis</kwd><kwd>arterial thrombosis</kwd><kwd>Behçet’s disease</kwd><kwd>Takayasu arteritis</kwd><kwd>granulomatosis with polyangiitis</kwd><kwd>eosinophilic granulomatosis with polyangiitis</kwd><kwd>microscopic polyangiitis</kwd><kwd>Henoch–Schönlein purpura</kwd><kwd>Kawasaki disease</kwd><kwd>polyarteritis nodosa</kwd><kwd>giant cell arteritis</kwd><kwd>Buerger’s disease</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>васкулиты</kwd><kwd>тромбоз</kwd><kwd>внеклеточные нейтрофильные ловушки</kwd><kwd>АНЦА-ассоциированные васкулиты</kwd><kwd>венозные тромбозы</kwd><kwd>артериальные тромбозы</kwd><kwd>болезнь Бехчета</kwd><kwd>артериит Такаясу</kwd><kwd>гранулематоз с полиангиитом</kwd><kwd>эозинофильный гранулематоз с полиангиитом</kwd><kwd>микроскопический полиангиит</kwd><kwd>пурпура Шенлейна–Геноха</kwd><kwd>болезнь Кавасаки</kwd><kwd>узелковый периартериит</kwd><kwd>гигантоклеточный артериит</kwd><kwd>болезнь Бюргера</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><citation-alternatives><mixed-citation xml:lang="en">Desbois A.C., Wechsler B., Cluzel P. et al. Cardiovascular involvement in Behçet’s disease. Rev Med Interne 2014;35(2): 103–11. DOI: 10.1016/j.revmed.2013.12.002. PMID: 24434015.</mixed-citation><mixed-citation xml:lang="ru">Desbois A.C., Wechsler B., Cluzel P. et al. Cardiovascular involvement in Behçet’s disease. Rev Med Interne 2014;35(2): 103–11. DOI: 10.1016/j.revmed.2013.12.002. PMID: 24434015.</mixed-citation></citation-alternatives></ref><ref id="B2"><label>2.</label><citation-alternatives><mixed-citation xml:lang="en">Ly K.H., Liozon E., Dalmay F. et al. Venous thrombosis in patients with giant cell arteritis: Features and outcomes in a cohort study. Joint Bone Spine 2017;84(3):323–6. DOI: 10.1016/j.jbspin.2016.04.011. PMID: 27324606.</mixed-citation><mixed-citation xml:lang="ru">Ly K.H., Liozon E., Dalmay F. et al. Venous thrombosis in patients with giant cell arteritis: Features and outcomes in a cohort study. Joint Bone Spine 2017;84(3):323–6. DOI: 10.1016/j.jbspin.2016.04.011. PMID: 27324606.</mixed-citation></citation-alternatives></ref><ref id="B3"><label>3.</label><citation-alternatives><mixed-citation xml:lang="en">Hwang J., Kim S.J., Bang O.Y. et al. Ischemic stroke in Takayasu's arteritis: lesion patterns and possible mechanisms. J Clin Neurol 2012;8(2):109–15. DOI: 10.3988/jcn.2012.8.2.109. PMID: 22787494.</mixed-citation><mixed-citation xml:lang="ru">Hwang J., Kim S.J., Bang O.Y. et al. Ischemic stroke in Takayasu's arteritis: lesion patterns and possible mechanisms. J Clin Neurol 2012;8(2):109–15. DOI: 10.3988/jcn.2012.8.2.109. PMID: 22787494.</mixed-citation></citation-alternatives></ref><ref id="B4"><label>4.</label><mixed-citation>Jennette J.C. Overview of the 2012 revised International Chapel Hill Consensus Conference nomenclature of vasculitides. Clin Exp Nephrol 2013;17(5):603–6. DOI: 10.1007/s10157-013-0869-6. PMID: 24072416.</mixed-citation></ref><ref id="B5"><label>5.</label><citation-alternatives><mixed-citation xml:lang="en">Ames P.R., Margaglione M., Mackie S., Alves J.D. Eosinophilia and thrombophilia in churg strauss syndrome: a clinical and pathogenetic overview. Clin Appl Thromb Hemost 2010;16(6):628–36. DOI: 10.1177/1076029609348647. PMID: 19833618.</mixed-citation><mixed-citation xml:lang="ru">Ames P.R., Margaglione M., Mackie S., Alves J.D. Eosinophilia and thrombophilia in churg strauss syndrome: a clinical and pathogenetic overview. Clin Appl Thromb Hemost 2010;16(6):628–36. DOI: 10.1177/1076029609348647. PMID: 19833618.</mixed-citation></citation-alternatives></ref><ref id="B6"><label>6.</label><mixed-citation>Weidner S., Hafezi-Rachti S., Rupprecht H.D. Thromboembolic events as a complication of antineutrophil cytoplasmic antibodyassociated vasculitis. Arthritis Rheum 2006;55(1):146–9. DOI: 10.1002/art.21704. PMID: 16463427.</mixed-citation></ref><ref id="B7"><label>7.</label><citation-alternatives><mixed-citation xml:lang="en">Allenbach Y., Seror R., Pagnoux C. et al. High frequency of venous thromboembolic events in Churg–Strauss syndrome, Wegener’s granulomatosis and microscopic polyangiitis but not polyarteritis nodosa: a systematic retrospective study on 1130 patients. Ann Rheum Dis 2009;68(4):564–7. DOI: 10.1136/ard.2008.099051. PMID: 19015208.</mixed-citation><mixed-citation xml:lang="ru">Allenbach Y., Seror R., Pagnoux C. et al. High frequency of venous thromboembolic events in Churg–Strauss syndrome, Wegener’s granulomatosis and microscopic polyangiitis but not polyarteritis nodosa: a systematic retrospective study on 1130 patients. Ann Rheum Dis 2009;68(4):564–7. DOI: 10.1136/ard.2008.099051. PMID: 19015208.</mixed-citation></citation-alternatives></ref><ref id="B8"><label>8.</label><mixed-citation>Stassen P.M., Derks R.P., Kallenberg C.G., Stegeman C.A. Venous thromboembolism in ANCA-associated vasculitis incidenceand risk factors. Rheumatology 2008;47(4):530–4. DOI: 10.1093/rheumatology/ken035. PMID: 18356178.</mixed-citation></ref><ref id="B9"><label>9.</label><citation-alternatives><mixed-citation xml:lang="en">Whyte A.F., Smith W.B., Sinkar S.N. et al. Clinical and laboratory characteristics of 19 patients with Churg-Strauss syndrome from a single South Australian centre. Intern Med J 2013;43(7):784-90. DOI: 10.1111/imj.12173. PMID: 23611179.</mixed-citation><mixed-citation xml:lang="ru">Whyte A.F., Smith W.B., Sinkar S.N. et al. Clinical and laboratory characteristics of 19 patients with Churg-Strauss syndrome from a single South Australian centre. Intern Med J 2013;43(7):784-90. DOI: 10.1111/imj.12173. PMID: 23611179.</mixed-citation></citation-alternatives></ref><ref id="B10"><label>10.</label><mixed-citation>Faurschou M., Obel N., Baslund B. High risk of pulmonary embolism and deep venous thrombosis but not of stroke in granulomatosis with polyangiitis (Wegener's). Arthritis Care Res (Hoboken) 2014;66(12):1910–4. DOI: 10.1002/acr.22423. PMID: 25073637.</mixed-citation></ref><ref id="B11"><label>11.</label><citation-alternatives><mixed-citation xml:lang="en">Morgan M.D., Turnbull J., Selamet U. et al. Increased incidence of cardiovascular events in patients with antineutrophil cytoplasmic antibody-associated vasculitides: a matched-pair cohort study. Arthritis Rheum 2009;60(11):3493–500. DOI: 10.1002/art.24957. PMID: 19877070.</mixed-citation><mixed-citation xml:lang="ru">Morgan M.D., Turnbull J., Selamet U. et al. Increased incidence of cardiovascular events in patients with antineutrophil cytoplasmic antibody-associated vasculitides: a matched-pair cohort study. Arthritis Rheum 2009;60(11):3493–500. DOI: 10.1002/art.24957. PMID: 19877070.</mixed-citation></citation-alternatives></ref><ref id="B12"><label>12.</label><citation-alternatives><mixed-citation xml:lang="en">Faurschou M., Mellemkjaer L., Soren- sen I.J. et al. Increased morbidity from ischemic heart disease in patients with Wegener’s granulomatosis. Arthritis Rheum 2009;60(4):1187–92. DOI: 10.1002/art.24386. PMID: 19333952.</mixed-citation><mixed-citation xml:lang="ru">Faurschou M., Mellemkjaer L., Soren- sen I.J. et al. Increased morbidity from ischemic heart disease in patients with Wegener’s granulomatosis. Arthritis Rheum 2009;60(4):1187–92. DOI: 10.1002/art.24386. PMID: 19333952.</mixed-citation></citation-alternatives></ref><ref id="B13"><label>13.</label><citation-alternatives><mixed-citation xml:lang="en">Suppiah R., Judge A., Batra R. et al. A model to predict cardiovascular events in patients with newly diagnosed Wegener’s granulomatosis and microscopic polyangiitis. Arthritis Care Res (Hoboken) 2011;63(4):588–96. DOI: 10.1002/acr.20433. PMID: 21452269.</mixed-citation><mixed-citation xml:lang="ru">Suppiah R., Judge A., Batra R. et al. A model to predict cardiovascular events in patients with newly diagnosed Wegener’s granulomatosis and microscopic polyangiitis. Arthritis Care Res (Hoboken) 2011;63(4):588–96. DOI: 10.1002/acr.20433. PMID: 21452269.</mixed-citation></citation-alternatives></ref><ref id="B14"><label>14.</label><citation-alternatives><mixed-citation xml:lang="en">Wang C., Chang D.Y., Chen M., Zhao M.H. HMGB1 contributes to glomerular endothelial cell injury in ANCA-associated vas culitis through enhancing endotheliumneutrophil interactions. J Cell Mol Med 2017;21(7):1351–60. DOI: 10.1111/jcmm.13065. PMID: 28181422.</mixed-citation><mixed-citation xml:lang="ru">Wang C., Chang D.Y., Chen M., Zhao M.H. HMGB1 contributes to glomerular endothelial cell injury in ANCA-associated vas culitis through enhancing endotheliumneutrophil interactions. J Cell Mol Med 2017;21(7):1351–60. DOI: 10.1111/jcmm.13065. PMID: 28181422.</mixed-citation></citation-alternatives></ref><ref id="B15"><label>15.</label><citation-alternatives><mixed-citation xml:lang="en">Kambas K., Chrysanthopoulou A., Vassilopoulos D. et al. Tissue factor expression in neutrophil extracellular traps and neutrophil derived microparticles in antineutrophil cytoplasmic antibody associated vasculitis may promote thromboinflammation and the thrombophilic state associated with the disease. Ann Rheum Dis 2014;73(10):1854–63. DOI: 10.1136/annrheumdis-2013-203430. PMID: 23873874.</mixed-citation><mixed-citation xml:lang="ru">Kambas K., Chrysanthopoulou A., Vassilopoulos D. et al. Tissue factor expression in neutrophil extracellular traps and neutrophil derived microparticles in antineutrophil cytoplasmic antibody associated vasculitis may promote thromboinflammation and the thrombophilic state associated with the disease. Ann Rheum Dis 2014;73(10):1854–63. DOI: 10.1136/annrheumdis-2013-203430. PMID: 23873874.</mixed-citation></citation-alternatives></ref><ref id="B16"><label>16.</label><mixed-citation>Legendre P., Régent A., Thiebault M. et al. Anti-endothelial cell antibodies in vasculitis: A systematic review. Autoimmun Rev 2017;16(2):146–53. DOI: 10.1016/j.autrev.2016.12.012. PMID: 27989761.</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Cugno M., Marzano A.V., Lorini M. et al. Enhanced tissue factor expression by blood eosinophils from patients with hypereosinophilia: a possible link with thrombosis. PLoS One 2014;9(11):e111862. DOI: 10.1371/journal.pone.0111862. PMID: 25375118.</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>Hao J., Wang C., Gou S.J. et al. The association between anti-plasminogen antibodies and disease activity in ANCA-associated vasculitis. Rheumatology (Oxford) 2014;53(2):300–6. DOI: 10.1093/rheumatology/ket345. PMID: 24162033.</mixed-citation></ref><ref id="B19"><label>19.</label><citation-alternatives><mixed-citation xml:lang="en">Hilhorst M., Winckers K., Wilde B. et al. Patients with antineutrophil cytoplasmic antibodies associated vasculitis in remission are hypercoagulable. J Rheumatol 2013;40(12):2042–6. DOI: 10.3899/jrheum.130200. PMID: 24128780.</mixed-citation><mixed-citation xml:lang="ru">Hilhorst M., Winckers K., Wilde B. et al. Patients with antineutrophil cytoplasmic antibodies associated vasculitis in remission are hypercoagulable. J Rheumatol 2013;40(12):2042–6. DOI: 10.3899/jrheum.130200. PMID: 24128780.</mixed-citation></citation-alternatives></ref><ref id="B20"><label>20.</label><mixed-citation>Davatchi F., Shahram F., Chams-Davatchi C. et al. Behcet’s disease: from east to west. Clin Rheumatol 2010;29(8):823–33. DOI: 10.1007/s10067-010-1430-6. PMID: 20354748.</mixed-citation></ref><ref id="B21"><label>21.</label><citation-alternatives><mixed-citation xml:lang="en">Saadoun D., Wechsler B. Behcet’s disease. Orphanet J Rare Dis 2012;7:20. DOI: 10.1186/1750-1172-7-20. PMID: 2249799.</mixed-citation><mixed-citation xml:lang="ru">Saadoun D., Wechsler B. Behcet’s disease. Orphanet J Rare Dis 2012;7:20. DOI: 10.1186/1750-1172-7-20. PMID: 2249799.</mixed-citation></citation-alternatives></ref><ref id="B22"><label>22.</label><mixed-citation>Cakmak O.S., Seyahi E., Kantarci F. et al. Venous severity assessment in Behçet’s syndrome. Clin Exp Rheumatol 2010;28(60):139. PMID: 23009740.</mixed-citation></ref><ref id="B23"><label>23.</label><citation-alternatives><mixed-citation xml:lang="en">Sarica-Kucukoglu R., Akdag-Kose A., Kayabal I.M. et al. Vascular involvement in Behcet’s disease: a retrospective analysis of 2319 cases. Int J Dermatol 2006;45(8):919–21. DOI: 10.1111/j.1365-4632.2006.02832.x. PMID: 16911374.</mixed-citation><mixed-citation xml:lang="ru">Sarica-Kucukoglu R., Akdag-Kose A., Kayabal I.M. et al. Vascular involvement in Behcet’s disease: a retrospective analysis of 2319 cases. Int J Dermatol 2006;45(8):919–21. DOI: 10.1111/j.1365-4632.2006.02832.x. PMID: 16911374.</mixed-citation></citation-alternatives></ref><ref id="B24"><label>24.</label><citation-alternatives><mixed-citation xml:lang="en">Calamia K.T., Schirmer M., Melikoglu M. Major vessel involvement in Behcet’s disease: an update. Curr Opin Rheumatol 2011;23(1):24–31. DOI: 10.1097/BOR.0b013e3283410088. PMID: 21124084.</mixed-citation><mixed-citation xml:lang="ru">Calamia K.T., Schirmer M., Melikoglu M. Major vessel involvement in Behcet’s disease: an update. Curr Opin Rheumatol 2011;23(1):24–31. DOI: 10.1097/BOR.0b013e3283410088. PMID: 21124084.</mixed-citation></citation-alternatives></ref><ref id="B25"><label>25.</label><citation-alternatives><mixed-citation xml:lang="en">Tunc R., Saip S., Siva A., Yazici H. Cerebral venous thrombosis is associated with major vessel disease in BS’s syndrome. Ann Rheum Dis 2004;63(12):1693–4. DOI: 10.1136/ard.2003.018515. PMID: 15547099.</mixed-citation><mixed-citation xml:lang="ru">Tunc R., Saip S., Siva A., Yazici H. Cerebral venous thrombosis is associated with major vessel disease in BS’s syndrome. Ann Rheum Dis 2004;63(12):1693–4. DOI: 10.1136/ard.2003.018515. PMID: 15547099.</mixed-citation></citation-alternatives></ref><ref id="B26"><label>26.</label><citation-alternatives><mixed-citation xml:lang="en">Saadoun D., Wechsler B., Resche-Rigon M. et al. Cerebral venous thrombosis in Behcet’s disease. Arthritis Rheum 2009;61(4):518–26. DOI: 10.1002/art.24393. PMID: 19333987.</mixed-citation><mixed-citation xml:lang="ru">Saadoun D., Wechsler B., Resche-Rigon M. et al. Cerebral venous thrombosis in Behcet’s disease. Arthritis Rheum 2009;61(4):518–26. DOI: 10.1002/art.24393. PMID: 19333987.</mixed-citation></citation-alternatives></ref><ref id="B27"><label>27.</label><citation-alternatives><mixed-citation xml:lang="en">Saadoun D., Wechsler B., Desseaux K. et al. Mortality in Behcet’s disease. Arthritis Rheum 2010;62(9):2806–12. DOI: 10.1002/art.27568. PMID: 20496419.</mixed-citation><mixed-citation xml:lang="ru">Saadoun D., Wechsler B., Desseaux K. et al. Mortality in Behcet’s disease. Arthritis Rheum 2010;62(9):2806–12. DOI: 10.1002/art.27568. PMID: 20496419.</mixed-citation></citation-alternatives></ref><ref id="B28"><label>28.</label><citation-alternatives><mixed-citation xml:lang="en">Desbois A.C., Wechsler B., Resche-Rigon M. et al. Immunosuppressants reduce venous thrombosis relapse in Behcet's disease. Arthritis Rheum 2012;64(8):2753–60. DOI: 10.1002/art.34450. PMID: 22354392.</mixed-citation><mixed-citation xml:lang="ru">Desbois A.C., Wechsler B., Resche-Rigon M. et al. Immunosuppressants reduce venous thrombosis relapse in Behcet's disease. Arthritis Rheum 2012;64(8):2753–60. DOI: 10.1002/art.34450. PMID: 22354392.</mixed-citation></citation-alternatives></ref><ref id="B29"><label>29.</label><citation-alternatives><mixed-citation xml:lang="en">Düzgün N., Ateş A., Aydintuğ O.T. et al. Characteristics of vascular involvement in Behçet's disease. Scand J Rheumatol 2006;35(1):65–8. DOI: 10.1080/03009740500255761. PMID: 16467046.</mixed-citation><mixed-citation xml:lang="ru">Düzgün N., Ateş A., Aydintuğ O.T. et al. Characteristics of vascular involvement in Behçet's disease. Scand J Rheumatol 2006;35(1):65–8. DOI: 10.1080/03009740500255761. PMID: 16467046.</mixed-citation></citation-alternatives></ref><ref id="B30"><label>30.</label><citation-alternatives><mixed-citation xml:lang="en">Ceyran H., Akcali Y., Kahraman C. Surgical treatment of vasculo-Behcet’s disease. A review of patients with concomitant multiple aneurysms and venous lesions. Vasa 2003;32(3):149–53. DOI: 10.1024/0301-1526.32.3.149. PMID: 14524035.</mixed-citation><mixed-citation xml:lang="ru">Ceyran H., Akcali Y., Kahraman C. Surgical treatment of vasculo-Behcet’s disease. A review of patients with concomitant multiple aneurysms and venous lesions. Vasa 2003;32(3):149–53. DOI: 10.1024/0301-1526.32.3.149. PMID: 14524035.</mixed-citation></citation-alternatives></ref><ref id="B31"><label>31.</label><mixed-citation>Mogulkoc N., Burgess M.I., Bishop P.W. Intracardiac thrombus in Behcet’s disease: a systematic review. Chest 2000;118(2):479–87. PMID:10936144.</mixed-citation></ref><ref id="B32"><label>32.</label><citation-alternatives><mixed-citation xml:lang="en">Silvestri E., Cenci C., Della Bella C. et al. Behçet’s syndrome: from pathogenesis to treatment. Milan: Springer-Verlag, 2014.</mixed-citation><mixed-citation xml:lang="ru">Silvestri E., Cenci C., Della Bella C. et al. Behçet’s syndrome: from pathogenesis to treatment. Milan: Springer-Verlag, 2014.</mixed-citation></citation-alternatives></ref><ref id="B33"><label>33.</label><citation-alternatives><mixed-citation xml:lang="en">Engelmann B., Massberg S. Thrombosis as an intravascular effector of innate immunity. Nat Rev Immunol 2013;13(1):3 4–45. DOI: 10.1038/nri3345. PMID: 23222502.</mixed-citation><mixed-citation xml:lang="ru">Engelmann B., Massberg S. Thrombosis as an intravascular effector of innate immunity. Nat Rev Immunol 2013;13(1):3 4–45. DOI: 10.1038/nri3345. PMID: 23222502.</mixed-citation></citation-alternatives></ref><ref id="B34"><label>34.</label><citation-alternatives><mixed-citation xml:lang="en">Butta N.V., Fernández-Bello I., LópezLongo F.J. et al. Endothelial dysfunction and altered coagulation as mediators of thromboembolism in Behçet disease. Semin Thromb Hemost 2015;41(6):621–8. DOI: 10.1055/s-0035-1556727. PMID: 26276934.</mixed-citation><mixed-citation xml:lang="ru">Butta N.V., Fernández-Bello I., LópezLongo F.J. et al. Endothelial dysfunction and altered coagulation as mediators of thromboembolism in Behçet disease. Semin Thromb Hemost 2015;41(6):621–8. DOI: 10.1055/s-0035-1556727. PMID: 26276934.</mixed-citation></citation-alternatives></ref><ref id="B35"><label>35.</label><citation-alternatives><mixed-citation xml:lang="en">Kose O. Development of Immunopathogenesis Strategies to Treat Behcet’s Disease. Patholog Res Int 2012;2012:261989. DOI: 10.1155/2012/261989. PMID: 22550612.</mixed-citation><mixed-citation xml:lang="ru">Kose O. Development of Immunopathogenesis Strategies to Treat Behcet’s Disease. Patholog Res Int 2012;2012:261989. DOI: 10.1155/2012/261989. PMID: 22550612.</mixed-citation></citation-alternatives></ref><ref id="B36"><label>36.</label><mixed-citation>Neves F.S., Spiller F. Possible mechanisms of neutrophil activation in Behçet’s disease. Int Immunopharmacol 2013;17(4):1206–10. DOI: 10.1016/j.intimp.2013.07.017. PMID: 23973446.</mixed-citation></ref><ref id="B37"><label>37.</label><mixed-citation>La Regina M., Orlandini F., Prisco D., Dentali F. Homocysteine in vascular Behcet disease: a meta-analysis. Arterioscler Thromb Vasc Biol 2010;30(10):2067–74. DOI: 10.1161/ATVBAHA.110.207068. PMID: 20634474.</mixed-citation></ref><ref id="B38"><label>38.</label><citation-alternatives><mixed-citation xml:lang="en">Jennette J.C., Falk R.J., Bacon P.A. et al. 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum 2013;65(1):1–11. DOI: 10.1002/art.37715. PMID: 23045170.</mixed-citation><mixed-citation xml:lang="ru">Jennette J.C., Falk R.J., Bacon P.A. et al. 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum 2013;65(1):1–11. DOI: 10.1002/art.37715. PMID: 23045170.</mixed-citation></citation-alternatives></ref><ref id="B39"><label>39.</label><mixed-citation>Avina-Zubieta J.A., Bhole V.M., Amiri N. et al. The risk of deep venous thrombosis and pulmonary embolism in giant cell arteritis: a general population-based study. Ann Rheum Dis 2016;75(1):148–54. DOI: 10.1136/annrheumdis-2014-205665. PMID: 25265937.</mixed-citation></ref><ref id="B40"><label>40.</label><citation-alternatives><mixed-citation xml:lang="en">Zoller B., Li X., Sundquist J. et al. Risk of pulmonary embolism in patients with autoimmune disorders: a nationwide follow-up study from Sweden. Lancet 2012;379(9812):244–9. DOI: 10.1016/S0140-6736(11)61306-8. PMID: 22119579.</mixed-citation><mixed-citation xml:lang="ru">Zoller B., Li X., Sundquist J. et al. Risk of pulmonary embolism in patients with autoimmune disorders: a nationwide follow-up study from Sweden. Lancet 2012;379(9812):244–9. DOI: 10.1016/S0140-6736(11)61306-8. PMID: 22119579.</mixed-citation></citation-alternatives></ref><ref id="B41"><label>41.</label><mixed-citation>Tomasson G., Peloquin C., Mohammad A. et al. Risk for cardiovascular disease early and late after a diagnosis of giant-cell arteritis: a cohort study. Ann Intern Med 2014;160(2):73–80. DOI: 10.7326/M123046. PMID: 24592492.</mixed-citation></ref><ref id="B42"><label>42.</label><mixed-citation>Gonzalez-Gay M.A., Pineiro A., GomezGigirey A. et al. Influence of traditional risk factors of atherosclerosis in the development of severe ischemic complications in giant cell arteritis. Medicine (Baltimore) 2004;83(6):342–7. PMID: 15525846.</mixed-citation></ref><ref id="B43"><label>43.</label><citation-alternatives><mixed-citation xml:lang="en">Gonzalez-Gay M.A., Vazquez-Rodriguez T.R., Gomez-Acebo I. et al. Strokes at time of disease diagnosis in a series of 287 patients with biopsy-proven giant cell arteritis. Medicine (Baltimore) 2009;88(4):227–35. DOI: 10.1097/MD.0b013e3181af4518. PMID: 19593228.</mixed-citation><mixed-citation xml:lang="ru">Gonzalez-Gay M.A., Vazquez-Rodriguez T.R., Gomez-Acebo I. et al. Strokes at time of disease diagnosis in a series of 287 patients with biopsy-proven giant cell arteritis. Medicine (Baltimore) 2009;88(4):227–35. DOI: 10.1097/MD.0b013e3181af4518. PMID: 19593228.</mixed-citation></citation-alternatives></ref><ref id="B44"><label>44.</label><citation-alternatives><mixed-citation xml:lang="en">Samson M., Jacquin A., Audia S. et al. Stroke associated with giant cell arteritis: a population-based study. J Neurol Neurosurg Psychiatry 2015;86(2):216–21. DOI: 10.1136/jnnp-2014-307614. PMID: 24780954.</mixed-citation><mixed-citation xml:lang="ru">Samson M., Jacquin A., Audia S. et al. Stroke associated with giant cell arteritis: a population-based study. J Neurol Neurosurg Psychiatry 2015;86(2):216–21. DOI: 10.1136/jnnp-2014-307614. PMID: 24780954.</mixed-citation></citation-alternatives></ref><ref id="B45"><label>45.</label><citation-alternatives><mixed-citation xml:lang="en">Udayakumar P.D., Chandran A.K., Crowson C.S. et al. Cardiovascular risk and acute coronary syndrome in giant cell arteritis: a population based retrospective cohort study. Arthritis Care Res (Hoboken) 2015;67(3):396–402. DOI: 10.1002/acr.22416. PMID: 25074472.</mixed-citation><mixed-citation xml:lang="ru">Udayakumar P.D., Chandran A.K., Crowson C.S. et al. Cardiovascular risk and acute coronary syndrome in giant cell arteritis: a population based retrospective cohort study. Arthritis Care Res (Hoboken) 2015;67(3):396–402. DOI: 10.1002/acr.22416. PMID: 25074472.</mixed-citation></citation-alternatives></ref><ref id="B46"><label>46.</label><citation-alternatives><mixed-citation xml:lang="en">Gonzalez-Gay M.A., Garcia-Porrua C., Gonzalez-Juanatey C. et al. Biopsy-proven giant cell arteritis patients with coronary artery disease have increased risk of aortic aneurysmal disease and arterial thrombosis. Clin Exp Rheumatol 2013;31(1 Suppl 75):S94. PMID: 23463922.</mixed-citation><mixed-citation xml:lang="ru">Gonzalez-Gay M.A., Garcia-Porrua C., Gonzalez-Juanatey C. et al. Biopsy-proven giant cell arteritis patients with coronary artery disease have increased risk of aortic aneurysmal disease and arterial thrombosis. Clin Exp Rheumatol 2013;31(1 Suppl 75):S94. PMID: 23463922.</mixed-citation></citation-alternatives></ref><ref id="B47"><label>47.</label><citation-alternatives><mixed-citation xml:lang="en">Hwang J., Kim S.J., Bang O.Y. et al. Ischemic stroke in Takayasu’s arteritis: lesion patterns and possible mechanisms. J Clin Neurol 2012;8(2):109–15. DOI: 10.3988/jcn.2012.8.2.109. PMID: 22787494.</mixed-citation><mixed-citation xml:lang="ru">Hwang J., Kim S.J., Bang O.Y. et al. Ischemic stroke in Takayasu’s arteritis: lesion patterns and possible mechanisms. J Clin Neurol 2012;8(2):109–15. DOI: 10.3988/jcn.2012.8.2.109. PMID: 22787494.</mixed-citation></citation-alternatives></ref><ref id="B48"><label>48.</label><mixed-citation>Ohta T., Ishioashi H., Hosaka M., Sugimoto I. Clinical and social consequences of Buerger disease. J Vasc Surg 2004;39(1):176–80. DOI: 10.1016/j.jvs.2003.08.006. PMID: 14718836.</mixed-citation></ref><ref id="B49"><label>49.</label><citation-alternatives><mixed-citation xml:lang="en">Adar R., Papa M.Z., Halpern Z. et al. Cellular sensitivity to collagen in thromboangiitis obliterans. N Engl J Med 1983;308(19):1113–6. DOI: 10.1056/NEJM198305123081901. PMID: 6835334.</mixed-citation><mixed-citation xml:lang="ru">Adar R., Papa M.Z., Halpern Z. et al. Cellular sensitivity to collagen in thromboangiitis obliterans. N Engl J Med 1983;308(19):1113–6. DOI: 10.1056/NEJM198305123081901. PMID: 6835334.</mixed-citation></citation-alternatives></ref><ref id="B50"><label>50.</label><mixed-citation>Klein-Weigel P.F., Bimmler M., Hempel P. et al. G-protein coupled receptor auto-antibodies in thromboangiitis obliterans (Buerger’s disease) and their removal by immunoadsorption. Vasa 2014;43(5): 347–52. DOI: 10.1024/0301-1526/a000372. PMID: 25147011.</mixed-citation></ref><ref id="B51"><label>51.</label><citation-alternatives><mixed-citation xml:lang="en">Małecki R., Kluz J., Przeździecka-Dołyk J. et al. The Pathogenesis and Diagnosis of Thromboangiitis obliterans: Is It Still a Mystery? Adv Clin Exp Med 2015;24(6):1085–97. DOI: 10.17219/ acem/33322. PMID: 26771983.</mixed-citation><mixed-citation xml:lang="ru">Małecki R., Kluz J., Przeździecka-Dołyk J. et al. The Pathogenesis and Diagnosis of Thromboangiitis obliterans: Is It Still a Mystery? Adv Clin Exp Med 2015;24(6):1085–97. DOI: 10.17219/ acem/33322. PMID: 26771983.</mixed-citation></citation-alternatives></ref><ref id="B52"><label>52.</label><citation-alternatives><mixed-citation xml:lang="en">Li L., Zhang J., Zhang Y., Ji H. Thrombosis warning in children suffering from henoch-schonlein purpura. Indian J Dermatol 2013;58(5):409. DOI: 10.4103/0019-5154.117349. PMID: 24082216.</mixed-citation><mixed-citation xml:lang="ru">Li L., Zhang J., Zhang Y., Ji H. Thrombosis warning in children suffering from henoch-schonlein purpura. Indian J Dermatol 2013;58(5):409. DOI: 10.4103/0019-5154.117349. PMID: 24082216.</mixed-citation></citation-alternatives></ref><ref id="B53"><label>53.</label><citation-alternatives><mixed-citation xml:lang="en">Kurotobi S., Kawakami N., Honda A. et al. Impaired vascular endothelium-dependent relaxation in Henoch-Schönlein purpura. Pediatr Nephrol 2004;19(2):138–43. DOI: 10.1007/s00467-003-1335-6. PMID: 14685839.</mixed-citation><mixed-citation xml:lang="ru">Kurotobi S., Kawakami N., Honda A. et al. Impaired vascular endothelium-dependent relaxation in Henoch-Schönlein purpura. Pediatr Nephrol 2004;19(2):138–43. DOI: 10.1007/s00467-003-1335-6. PMID: 14685839.</mixed-citation></citation-alternatives></ref><ref id="B54"><label>54.</label><citation-alternatives><mixed-citation xml:lang="en">Yilmaz D., Kavakli K., Ozkayin N. The elevated markers of hypercoagulability in children with Henoch-Schönlein purpura. Pediatr Hematol Oncol 2005;22(1):41–8. PMID: 15770830.</mixed-citation><mixed-citation xml:lang="ru">Yilmaz D., Kavakli K., Ozkayin N. The elevated markers of hypercoagulability in children with Henoch-Schönlein purpura. Pediatr Hematol Oncol 2005;22(1):41–8. PMID: 15770830.</mixed-citation></citation-alternatives></ref><ref id="B55"><label>55.</label><citation-alternatives><mixed-citation xml:lang="en">Sanchez-Manubens J., Bou R., Anton J. Diagnosis and classification of Kawasaki disease. J Autoimmun 2014;48–49:113–7. DOI: 10.1016/j.jaut.2014.01.010. PMID: 24485156.</mixed-citation><mixed-citation xml:lang="ru">Sanchez-Manubens J., Bou R., Anton J. Diagnosis and classification of Kawasaki disease. J Autoimmun 2014;48–49:113–7. DOI: 10.1016/j.jaut.2014.01.010. PMID: 24485156.</mixed-citation></citation-alternatives></ref><ref id="B56"><label>56.</label><citation-alternatives><mixed-citation xml:lang="en">Adler A.C., Kodavatiganti R. Kawasaki disease and giant coronary artery aneurysms: the role of echocardiography from diagnosis through follow-up. Echocardiography 2016;33(8):1245–50. DOI: 10.1111/echo.13271. PMID: 27357568.</mixed-citation><mixed-citation xml:lang="ru">Adler A.C., Kodavatiganti R. Kawasaki disease and giant coronary artery aneurysms: the role of echocardiography from diagnosis through follow-up. Echocardiography 2016;33(8):1245–50. DOI: 10.1111/echo.13271. PMID: 27357568.</mixed-citation></citation-alternatives></ref><ref id="B57"><label>57.</label><mixed-citation>Bachlava E., Loukopoulou S., Karanasios E. et al. Management of coronary artery aneurysms using abciximab in children with Kawasaki disease. Int J Cardiol 2016;220:65–9. DOI: 10.1016/j. ijcard.2016.06.062 PMID: 27372045.</mixed-citation></ref></ref-list></back></article>
